Researchers at Roswell Park Comprehensive Cancer Center found that mitochondrial unfolded protein response—a unique longevity function of mitochondria—could be a target for the treatment and management of metastatic, resistant, or recurrent prostate cancer.
The Decipher Prostate Genomic Classifier predicts which patients with metastatic cancer are likely to benefit from treatment intensification with the chemotherapy docetaxel and which are not likely to benefit and can therefore avoid unnecessary toxicity, according to findings by University College London and Veracyte, Inc., a genomic diagnostic company.
